COMPARISON OF BLOOD PARAMETERS IN LIVER
TRANSPLANT PATIENTS WITH AND WITHOUT
COVID-19 INFECTION
Nona N. Yurukova1, Krasimira S. Prodanova2 1 University Hospital “Lozenets”
Sofia - 1407, BULGARIA 2 Technical University of Sofia
Sofia - 1000, BULGARIA
The available data on COVID-19 infection in liver transplant (LT) recipients are not conclusive and are limited to several case series. Transplant recipients are considered as “clinically extremely vulnerable” sub-population for COVID-19 because of lifelong immunosuppressive therapy and their higher rate of underlying comorbidities. We collected data from a Bulgarian liver transplant program at a single center for adult recipients of LT who were followed up from May, 2020, through May, 2022 despite the pandemic environment. The current study aims analyzing the statistically significant differences in over 50 biochemical blood parameters between cohorts of liver transplant patients with SARS-CoV-2 infection and LT patients without symptoms of infection.
You will need Adobe Acrobat reader. For more information and free download of the reader, please follow this link.
References
[1] G. Snedecor, W. Cochran, Statistical Methods, Iowa State University Press,
Iowa (1989).
[2] H. Lilliefors, On the Kolmogorov-Smirnov test fornormality with mean
and variance unknown, Journal of the American Statistical Association,
62 (1967), 399-402.
[4] R. Opsomer, D. Kuypers, COVID-19 and solid organ transplantation:
Finding the right balance, Transplant Rev (Orlando), 36, No 3 (2022),
Art. 100710; doi: 10.1016/j.trre.2022.100710.
[5] K. Starke, D. Reissig, G. Petereit-Haack, S. Schmauder, A. Nienhaus, A.
Seidler, The isolated effect of age on the risk of COVID-19 severe outcomes: A systematic review with meta-analysis, BMJ Glob. Health, 6, No
12 (2021), e006434; doi: 10.1136/bmjgh-2021-006434.
[6] G. Webb, T. Marjot, J. Cook, C. Aloman, M. Armstrong, E. Brenner,
Outcomes following SARS-CoV-2 infection in liver transplant recipients:
An international registry study, Lancet Gastroenterol Hepatol, 5, No 1
(2020), 1008-1016; doi: 10.1016/S2468-1253(20)30271-5.
[7] B. Boyarsky, W. Werbel, R. Avery, A. Tobian, A. Massie, D. Segev, Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients, JAMA, 325, No 21 (2021); 2204-2206; doi:
10.1001/jama.2021.7489.
[8] E. Hincal, B. Kaymakamzade, N. Gokbulut, Humidity level on Covid-19
with control strategies, International Journal of Applied Mathematics, 34,
No 4 (2021), 795-802; doi:10.12732/ijam.v34i4.14.
[9] M. Ivanova, L. Dospatliev, Data analytics and Sir modeling of Covid-19 in
Bulgaria, International Journal of Applied Mathematics, 33, No 6 (2020),
1099-1114; doi: 10.12732/ijam.v33i6.10.
[10] L. Lazarova, N. Stoikovikj, A. Stojanova, M. Mileva, M. Ljubenovska, Mathematical model for prediction of Covid-19 dynamics, International
Journal of Applied Mathematics, 35, No 1 (2022), 119-133;
doi:10.12732/ijamv35i1.9.